NEW YORK (GenomeWeb News) – South Korean firm Panagene today said that it has signed an agreement to provide Dako with Peptide Nucleic Acid probes for use in diagnostic or research products.
PNA is an artificially synthesized DNA analogue that Panagene said has higher binding affinity, specificity, and sensitivity to a target, as well as high biological/chemical stability. Terms of the agreement were not disclosed.
Dako currently offers a telomere PNA kit for flow cytometry, which measures telomeric sequences in vertebrate interphase hematopoietic cells, a PNA ISH detection kit for performing in situ hybridization, and an Epstein-Barr Virus PNA Probe/Fluorescein product for detecting the two nuclear RNA transcripts EBER1 and EBER2 encoded by Epstein-Barr virus.
Dako is part of Agilent Technologies, following a $2.2 billion acquisition last year.